Quantcast
Last updated on April 19, 2014 at 12:41 EDT

Latest Kidney tumour Stories

2013-04-02 12:30:43

microRNA-based diagnostic assays for classifying renal cell tumors and for classifying tumors from patients with cancer of unknown or uncertain primary to be featured in poster session on April 7 PHILADELPHIA and REHOVOT, Israel, April 2, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters related to the Company's microRNA-based diagnostic assays will be featured at the...

2013-03-12 08:30:31

PHILADELPHIA and REHOVOT, Israel, March 12, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Ken Berlin, President and Chief Executive Officer of the Company, will present a corporate overview at the 25th Annual Roth Conference taking place from March 17-20, 2013 at the Ritz-Carlton Laguna Niguel in California. Mr. Berlin's presentation will take place on Tuesday, March 19(th) at 4:30...

2013-01-04 08:23:16

PHILADELPHIA and REHOVOT, Israel, Jan. 4, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Kenneth A. Berlin, President and CEO, is scheduled to present a corporate overview at Sidoti & Company's 2013 Micro-Cap Conference on Monday, January 7, 2013 at The Grand Hyatt Hotel in New York City. The Rosetta Genomics presentation is scheduled for 9:20 a.m. Eastern Time. The Company's...

2012-12-29 05:00:59

Drs. William Y. Kim, of UNC, and James W. Mier, of Harvard, will each receive $250,000 grants to support innovative, translational kidney cancer research. Newport Beach, CA (PRWEB) December 28, 2012 The American Association for Cancer Research and Kure It are pleased to announce that William Y. Kim, M.D., and James W. Mier, M.D., will each receive a 2012 AACR-Kure It Grant for Kidney Cancer Research. Kim, assistant professor in the departments of medicine and genetics at the University of...

2011-06-08 06:51:45

(Ivanhoe Newswire) -- About 50,000 Americans are diagnosed with kidney cancer every year, but a new form of radioimmuntherapy may decrease this number significantly. Radioimmunotherapy zeroes in on antigens associated with kidney cancer cells. Patients with progressive kidney cancer receiving as much as three times the dosage show dramatic slowing of cancer growth and stabilization of their disease. "This study is another step forward in developing a cancer therapy that has the potential to...

2011-05-19 22:55:59

Researchers at the University of Oxford have developed a cheap and reliable diagnostic test for a rare form of cancer. The test involves screening tumour samples for a particular molecular fingerprint unique to this type of cancer. Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder which causes the development of benign but often painful tumours in the skin and, in females, in the uterus. Between one in six and one in ten people affected by the disorder will go on to...

2010-11-19 00:00:46

Galil Medical's TRACE Renal Registry tracks the use and effectiveness of kidney cryotherapy. Arden Hills, MN (PRWEB) November 18, 2010 Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that Medical University of South Carolina enrolled their first TRACE Registry patient. The TRACE (Tracking Renal Tumors After Cryoablation Evaluation) Registry will allow physicians and the company to follow and evaluate the use and effectiveness of...

2010-10-21 00:00:41

Galil Medical's TRACE Renal Registry tracks the use and effectiveness of kidney cryotherapy. Arden Hills, MN (PRWEB) October 20, 2010 Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that Columbia University Medical Center enrolled their first TRACE Registry patient. The TRACE (Tracking Renal Tumors After Cryoablation Evaluation) Registry will allow physicians and the company to follow and evaluate the use and effectiveness of cryotherapy...

2010-06-02 15:19:48

Kidney cancer is a radiographic diagnosis which means treatment decisions are often made based on the findings of a solid mass on CT or MRI. Unfortunately these tests cannot distinguish the different types of kidney cancers which have variable risks. As more Americans continue to be scanned as part of their evaluation for various ailments and symptoms, the number of kidney tumors found serendipitously has increased such that now up to 70 percent of kidney cancers are discovered incidentally....

2010-05-28 17:51:22

Small but decisive study highlights differences in clear- and non-clear cell subtypes Of the more than 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year, approximately 20 percent have non-clear cell forms of the disease. New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC, responds differently to sunitinib "“ a standard frontline treatment for RCC. In a small but decisive Phase II trial, the...